Anna J Henningsson Selected Research

Lyme Neuroborreliosis

7/2022	Brain damage markers neuron-specific enolase (NSE) and S100B in serum in children with Lyme neuroborreliosis-detection and evaluation as prognostic biomarkers for clinical outcome.
5/2022	Clinical performance and analytical accuracy of a C6 peptide-based point-of-care lateral flow immunoassay in Lyme borreliosis serology.
1/2022	CXCL13 in laboratory diagnosis of Lyme neuroborreliosis-the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples.
11/2021	Molecular Detection of Borrelia Bacteria in Cerebrospinal Fluid-Optimisation of Pre-Analytical Sample Handling for Increased Analytical Sensitivity.
6/2021	Serodiagnosis of Lyme borreliosis-is IgM in serum more harmful than helpful?
3/2020	Cerebrospinal fluid cytokines and chemokines in children with Lyme neuroborreliosis; pattern and diagnostic utility.
1/2020	Cytokines and chemokines in cerebrospinal fluid in relation to diagnosis, clinical presentation and recovery in children being evaluated for Lyme neuroborreliosis.
10/2018	The chemokine CXCL13 in cerebrospinal fluid in children with Lyme neuroborreliosis.
1/2018	Subclinical Lyme borreliosis is common in south-eastern Sweden and may be distinguished from Lyme neuroborreliosis by sex, age and specific immune marker patterns.
1/2017	Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anna J Henningsson Research Topics

Disease

13	Lyme Neuroborreliosis 07/2022 - 02/2011
6	Leukocytosis (Pleocytosis) 07/2022 - 02/2011
4	Inflammation (Inflammations) 03/2020 - 02/2007
3	Lyme Disease (Disease, Lyme) 05/2022 - 01/2018
2	Coinfection 01/2021 - 01/2021
2	Anaplasmosis 01/2021 - 09/2018
2	Relapsing Fever 01/2021 - 01/2017
1	COVID-19 01/2022
1	Bartonella Infections (Bartonellosis) 01/2021
1	Infections 01/2021
1	Babesiosis (Piroplasmosis) 01/2021
1	Rickettsia Infections 01/2021
1	Tularemia 01/2021
1	Tick-Borne Diseases (Tick-Borne Disease) 01/2021

Drug/Important Bio-Agent (IBA)

7	AntibodiesIBA 07/2022 - 02/2011
4	Chemokine CXCL13IBA 01/2022 - 02/2011
4	CytokinesIBA 03/2020 - 04/2011
4	ChemokinesIBA 03/2020 - 04/2011
3	Biomarkers (Surrogate Marker)IBA 07/2022 - 01/2018
2	Complement System Proteins (Complement)IBA 01/2022 - 02/2007
2	Interleukin-17 (Interleukin 17)IBA 01/2017 - 04/2011
1	Phosphopyruvate Hydratase (Enolase)IBA 07/2022
1	Peptides (Polypeptides)IBA 05/2022
1	Abiraterone AcetateIBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	enzalutamideIBA 01/2022
1	AndrogensIBA 01/2022
1	bicalutamide (Casodex)FDA LinkGeneric 01/2022
1	Testosterone (Sustanon)FDA Link 01/2022
1	Androgen Antagonists (Antiandrogens)IBA 01/2022
1	Immunoglobulin M (IgM)IBA 06/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	tert-butylserineIBA 01/2021
1	Bacterial DNAIBA 09/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2017
1	Complementary DNA (cDNA)IBA 01/2017
1	ImmunosorbentsIBA 11/2016
1	EnzymesIBA 11/2016

Therapy/Procedure

1	Critical Care (Surgical Intensive Care) 01/2022
1	Therapeutics 01/2022